Hanamura I - Search Results

1

[Advances in multiple myeloma molecular biology research].

Hanamura I. Hanamura I. Rinsho Ketsueki. 2019;60(9):1236-1242. doi: 10.11406/rinketsu.60.1236. Rinsho Ketsueki. 2019. PMID: 31597849 Review. Japanese.

2

A novel human multiple myeloma-derived cell line, NCU-MM-1, carrying t(2;11)(q11;q23) and t(8;22)(q24;q11) chromosomal translocations with overexpression of c-Myc protein.

Iida S, Hanamura I, Suzuki T, Kamiya T, Kato M, Hayami Y, Miura K, Harada S, Tsuboi K, Wakita A, Akano Y, Taniwaki M, Nitta M, Ueda R. Iida S, et al. Among authors: hanamura i. Int J Hematol. 2000 Jul;72(1):85-91. Int J Hematol. 2000. PMID: 10979215

3

[The molecular mechanisms of myelomagenesis].

Hanamura I, Iida S. Hanamura I, et al. Nihon Rinsho. 2007 Jan 28;65 Suppl 1:203-14. Nihon Rinsho. 2007. PMID: 17474414 Review. Japanese. No abstract available.

4

[Molecular pathogenesis of myeloma for the therapeutic targets].

Hanamura I. Hanamura I. Nihon Rinsho. 2007 Dec;65(12):2202-8. Nihon Rinsho. 2007. PMID: 18069261 Review. Japanese.

5

[Multiple melanoma-progress in understanding of molecular mechanism and improvement in treatment outcome with introduction of new drugs for multiple myeloma].

Hanamura I, Iida S. Hanamura I, et al. Gan To Kagaku Ryoho. 2010 May;37(5):816-21. Gan To Kagaku Ryoho. 2010. PMID: 20524255 Japanese. No abstract available.

6

[Genetic and cytogenetic abnormalities of multiple myeloma].

Hanamura I, Iida S. Hanamura I, et al. Nihon Rinsho. 2012 Apr;70 Suppl 2:126-32. Nihon Rinsho. 2012. PMID: 23133940 Japanese. No abstract available.

7

[Classification and genetic abnormalities of multiple myeloma].

Hanamura I, Iida S. Hanamura I, et al. Nihon Rinsho. 2015 Jan;73(1):17-27. Nihon Rinsho. 2015. PMID: 25626298 Review. Japanese.

8

Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cells.

Mizuno S, Hanamura I, Ota A, Karnan S, Narita T, Ri M, Mizutani M, Goto M, Gotou M, Tsunekawa N, Shikami M, Iida S, Hosokawa Y, Miwa H, Ueda R, Nitta M, Takami A. Mizuno S, et al. Among authors: hanamura i. Int J Hematol. 2015 Nov;102(5):569-78. doi: 10.1007/s12185-015-1859-0. Epub 2015 Sep 4. Int J Hematol. 2015. PMID: 26341959

9

Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).

Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: hanamura i. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.

10

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K. Iida S, et al. Among authors: hanamura i. Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17. Cancer Sci. 2018. PMID: 29478257 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

83 results

Search Page